Pfizer Czech Republic made a net profit of CZK CZK 134 mil under revenues of CZK 4,947 mil in 2014, down 7.25% and -8.51%, respectively, when compared to the last year.
This translates into a net margin of 2.70%. Historically, the firm’s net margin reached an all time high of 7.17% in 2003 and an all time low of -30.0% in 2002. The average net margin in the last five years amounted to 2.36%.
On the operating level, EBITDA margin reached 3.44% and EBIT amounted to 3.48% of sales in 2014.
As far as Pfizer Czech Republic's peers are concerned, Roche Czech Republic posted net and EBITDA margin of 2.17% and 6.07%, respectively in 2014, Bayer Czech Republic generated margins of 2.64% and 3.53% and Amgen Czech Republic's profit margin reached 6.36% on the net and 8.55% on the EBITDA level in 2014.